Novartis’ Secukinumab Receives EC Approval as First Novel Therapy for Hidradenitis Suppurativa in Nearly a Decade
Novartis
Drug Development and Manufacturing
European Commission
The European Commission, abbreviated as the EU Commission, is a supranational body under the European Union. Within the EU political system, the European Commission primarily undertakes executive tasks, thus being roughly equivalent to the government in a national system. However, the European Commission has other functions as well. In particular, except for the few circumstances specified in the treaties, the European Commission is the only institution with legislative power in the EU legislative process.
On June 1, Novartis announced that the European Commission (EC) has approved secukinumab (trade name: Cosentyx) for the treatment of adult patients with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapies.Novartis Press Release Shows That...Youdankang is in the recent decadeThe first novel therapy for Hidradenitis Suppurativa (HS).
The EU's approval this time is mainly based on the positive results of the SUNSHINE and SUNRISE studies. SUNSHINE and SUNRISE are two randomized, double-blind, placebo-controlled, multi-center Phase III clinical trials involving 219 sites across 40 countries. Among them, 541 subjects were included in the analysis for SUNSHINE, and 543 subjects were included in the analysis for SUNRISE. The specific treatment regimens are as follows:
Subjects were randomly assigned in a 1:1:1 ratio to receive secukinumab 300 mg every 2 weeks (Q2W group) or every 4 weeks (Q4W group) or placebo (placebo group), with daily topical antibiotics as adjuvant therapy. After the 16-week treatment period, patients in each group could continue treatment until week 52 to assess long-term efficacy; the Q2W and Q4W groups maintained their original dosing regimens, while the placebo group switched to secukinumab 300 mg Q2W or Q4W.
The primary endpoint was the HS response rate at Week 16, with response defined as a ≥50% reduction in the number of abscesses and inflammatory nodules, or no increase in the number of abscesses or sinus tracts compared to baseline.
Results Showed that the Q2W Groups in Both Studies Reached the Primary Efficacy Endpoint. In the SUNSHINE study, the HS response rate in the Q2W group was 45%, significantly higher than 34% in the placebo group; in the SUNRISE study, the HS response rate in the Q2W group was 42%, also significantly higher than 31% in the placebo group. In the Q4W group, the HS response rate in the SUNSHINE study was 42%, showing no significant difference compared to 34% in the placebo group; in the SUNRISE study, the HS response rate was 46%, significantly higher than 31% in the placebo group.
At Week 52, the HS response rate in the Q2W group of the SUNSHINE study increased to 76%, and to 81% in the Q4W group; in the SUNRISE study, the HS response rate in the Q2W group rose to 84%, and to 77% in the Q4W group. In terms of safety, the most common AEs in both trials were headaches. In summary, secukinumab demonstrated a favorable safety profile, consistent with previous reports, with no new safety signals identified.
Secukinumab: The world's first fully human interleukin inhibitor, which can specifically neutralize IL-17A from various sources, inhibiting its pro-inflammatory effects to treat multiple autoimmune diseases. It has been approved for several indications including psoriatic arthritis and radiographic-negative axial spondyloarthritis. According to Novartis' financial report, the product's sales in 2022 reached $4.788 billion.
Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.